問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Tri-Service General Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2019-04-01 - 2022-12-31
Condition/Disease
non-squamous non-small cell lung cancer
Test Drug
Durvalumab、Tremelimumab
Participate Sites8Sites
Recruiting8Sites
Division of General Internal Medicine
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
Participate Sites9Sites
2011-08-01 - 2014-07-31
Participate Sites5Sites
Terminated5Sites
2008-01-19 - 2009-11-18
Participate Sites2Sites
Terminated2Sites
2014-05-06 - 2018-11-12
Participate Sites1Sites
Terminated1Sites
2007-06-01 - 2009-02-28
Participate Sites4Sites
Terminated4Sites
2009-09-15 - 2010-06-30
Participate Sites3Sites
Terminated3Sites
2012-04-01 - 2013-12-31
2011-07-01 - 2014-08-30
2010-08-01 - 2011-05-31
全部
